Stryker's Growth Momentum Clashes with High Valuation and Near-Term Risks

What happened

Stryker continues to exhibit strong double-digit sales growth into 2026, driven by robust robotics demand and MedSurg expansion, as highlighted in recent analysis. However, the DeepValue report reveals a significant valuation disconnect, with the stock trading at ~46x P/E and ~30x EV/EBITDA, far above the DCF intrinsic value of ~$124 per share. Near-term headwinds include tariff impacts estimated at $175-200 million, vascular segment weaknesses, and international hurdles that could pressure margins. Despite strategic acquisitions like Inari to bolster vascular growth, execution risks and past goodwill impairments, such as the $977 million write-down in spine, raise concerns about capital allocation. This creates a tension between Stryker's operational strengths and its elevated multiple, which leaves little room for error amid competitive and macroeconomic pressures.

Implication

Stryker's robust growth and leadership in robotics provide a durable competitive advantage, but the stock's premium pricing demands flawless execution to justify future returns. Tariff headwinds and integration challenges from recent acquisitions could erode earnings and trigger multiple compression, especially if growth slows or impairments recur. Long-term holders might benefit from the company's strategic shifts, but must closely monitor vascular adoption and competitive dynamics in robotics. For value-oriented investors, the lack of margin of safety suggests waiting for a valuation reset or clearer evidence of sustained profitability post-integration. Overall, maintaining a cautious stance with potential position reductions is prudent until risks are better priced in.

Thesis delta

The recent news emphasizes Stryker's growth trajectory but does not alter the core valuation concerns identified in the DeepValue report, which maintains a 'POTENTIAL SELL' stance due to limited margin of safety. This reinforces the view that while operational momentum is positive, investors should not be swayed by bullish narratives without addressing the high multiple and near-term headwinds. No fundamental shift in investment thesis is warranted; instead, the focus remains on potential downside risks from tariffs and execution missteps.